Navigation Links
Australian Patent Office Grants Patent Covering RoosterBio’s Novel Compositions and Formulations for Ready-to-Print (RTP) Cells

RoosterBio Inc, a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent approval in Australia for novel product formulations related to “Ready-to-Print” (RTP) cellular product formats (patent number AU 2015259373). This new patent adds intellectual property (IP) protection, including methods, uses and compositions in Australia. The RoosterRTP™ patent application has also been filed in the United States, Europe, South Korea, Japan, Canada, Israel and China.

“This is a significant and exciting decision for RoosterBio because this patent represents foundational technology related to biopreserved formulations of cells for tissue engineering and bioprinting applications,” said Jon A. Rowley, PhD, RoosterBio’s Founder and Chief Product Officer. “Issuance of this patent strengthens our leading intellectual property portfolio and further validates RoosterBio’s novel technology platform for accelerating regenerative medicine.”

Bioprinting of living cells and tissues creates unique product requirements related to shelf life and printability of living cells. RoosterBio was the first to launch a “ready-to-print” product formulation, RoosterRTP™, allowing bioprinters and tissue engineers to thaw and use large quantities of hMSCs for same day experiments, avoiding time-, labor- and cost-intensive cell expansion processes. “The most significant challenge in the advancement of 3D bioprinting has been the scarce availability of living cellular biomaterials for printing. Until RoosterBio, generating hMSCs would take a significant amount of time to culture and expand cells for the bioprinting process. With RoosterRTP™, we’re radically simplifying the most complex and labor-intensive aspects of bioprinting, saving users weeks of culture time and driving down the cost of cellular bioprinting.” Dr. Rowley added, “Our vision is a world where safe and effective regenerative medicines are rapidly developed and are widely available on a global scale, to benefit the lives of patients in need.”

RoosterRTP™ has been used by multiple customers, including the U.S. Military, to bring next-generation critical wound care closer to forward-deployed military positions.

For more information about RoosterRTP™, please visit

About RoosterBio, Inc
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology news :

1. Climate tug of war disrupting Australian atmospheric circulation patterns
2. Scientists find that dolphin in Australian waters is a new species
3. Australian marine reserves provide safe passageway for endangered species
4. Glycomics Institute to assist Australian sugar industry
5. Scientists name new species of cetacean: The Australian humpback dolphin
6. Nutrition an issue for Indigenous Australians
7. Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study
8. Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan
9. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
10. Patent issued for beneficial animal candy
11. Patent awarded today to NJIT for novel use of water jets to create high tensile strength alloy parts
Post Your Comments:
(Date:10/10/2019)... ... October 10, 2019 , ... ... ultrasound, invites attendees of the American Society of Anesthesiologists 2019 Annual Meeting to ... on October 19-21 in Orlando, Florida, and will provide more than 14,000 healthcare ...
(Date:10/8/2019)... (PRWEB) , ... October 07, 2019 , ... The future ... to the genetic level, resulting in people living longer, healthier lives. But it will ... on earth. , Leroy E. Hood, MD, PhD, Chief Strategy Officer and Co-Founder of ...
(Date:10/3/2019)... ... October 02, 2019 , ... Personalized Stem Cells, ... patient in an FDA approved clinical trial for stem cell treatment of knee ... formation of the company as a subsidiary of VetStem Biopharma. , PSC CEO, Michael ...
Breaking Biology News(10 mins):
(Date:10/10/2019)... , ... October 09, 2019 , ... ... Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote speaker for ... 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist and palliative ...
(Date:10/10/2019)... ... October 10, 2019 , ... R3 Stem Cell announces it has ... October 18-19th, 2019 in Las Vegas with spots still open. , The speaker, Dr. ... several Ivy League universities including Cornell, Harvard and Dartmouth. He currently serves as the ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... Madhumita Suresh and Leslie Maurer presented company executives with a set of recommendations ... (MBS) graduates will offer insights from their TMP to a wider audience of ...
(Date:10/8/2019)... ... October 08, 2019 , ... Today, Massachusetts stem cell biotechnology company ... technology. Like the company’s precursor patent, approved in the U.S. in 2017, the ... stem cells. Asymmetrex now markets the technology in the U.S. as the AlphaSTEM ...
Breaking Biology Technology: